Press Releases - Emmaus Medical, Inc.

Emmaus Life Sciences Receives FDA Approval for Endari® Label EnhancementsJune 26, 2025

Changes Based on Additional Pharmacokinetics Data

Emmaus Life Sciences Reports Quarterly Financial ResultsMay 15, 2025

Emmaus Life Sciences, Inc., today reported on its financial condition and results of operations as of and for the three months ended March 31, 2025.

Emmaus Life Sciences Reports 2024 Financial ResultsApril 14, 2025

Emmaus Life Sciences, Inc., today reported on its financial condition and results of operations as of and for the year ended December 31, 2024.

Emmaus Life Science Reports Grant of Endari Market Exclusivity In Kingdom of Saudi ArabiaJanuary 29, 2025

Initial One-Year Exclusivity Period Will Be Extended to Three Years if Endari is Approved for Marketing

Emmaus Life Sciences Reports Improved Quarterly Financial ResultsNovember 19, 2024

Emmaus Life Sciences, Inc., today reported on its financial condition and results of operations as of and for the three and nine months ended September 30, 2024.